Balance Training in Chronic Obstructive Pulmonary Disease

April 14, 2026 updated by: Istituti Clinici Scientifici Maugeri SpA

Balance Training: Its Effect on Pulmonary Rehabilitation of Elderly Subjects With Chronic Obstructive Pulmonary Disease

The aim of the study will be to verify whether the addition of an exercise program aimed to improve balance can reduce the risk of falling in subjects with COPD over 80 years of age compared to the standard rehabilitation program. Patients will be randomly assigned in two groups (intervention and control). The pulmonary rehabilitation (PR) program is organized in accordance with current guidelines.

Study Overview

Detailed Description

Chronic Obstructive Pulmonary Disease-COPD is the most prevalent pathology among chronic airway diseases. The average age of life has increased. Subjects over 80 years old have peculiar characteristics. Individuals with COPD have an increased risk of falling compared with healthy peers. A pulmonary rehabilitation program reduces the risk of falling as measured by gait speed. Balance training on the elderly has been shown to be effective in improving muscle strength, coordination, balance and in reducing the risk and number of falls and the fear of falling.

The enrolled subjects will complete an in-patient PR program according to enrollment.

Control: education, aerobic and strength training and callisthenic exercises. Intervention: education, aerobic and strength training as group Control and balance training. At baseline will be recorded: demographics and anthropometrics, comorbidities, drug therapy, flow/volume curve, arterial blood gases, serum hemoglobin, history of fall, exacerbations and risk of sarcopenia. Before and after the PR the following outcome measures will be assessed: balance performance, peripheral muscle strength, gait speed, health status, dyspnea, quality of life, exercise capacity, confidence with balance and perceived change. Sample size calculation was performed based on the primary endpoint of the study. We estimate a number of 50 subjects.

Study Type

Interventional

Enrollment (Actual)

21

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Varese
      • Tradate, Varese, Italy, 21049
        • Department of pulmonary rehabilitation

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age ≥ 80 years old,
  • Diagnosis of COPD according to GOLD Guidelines (Tiffenau Index <70%) under optimized medical treatment,
  • Able to perform and complete study procedures.

Exclusion Criteria:

  • Anticholinergic Cognitive Burden score ≥3,
  • Mini-Mental State Examination <22,
  • Acute or chronic impairment and/or medical diseases that are likely to preclude exercise testing and PR.
  • Brain lesions,
  • Inner ear disease
  • Visual deficit,
  • Lower limb surgery in the previous 6 months.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Control
Educational interventions, aerobic and strenght training, flexibility exercises.
Educational interventions, 3 individual sessions of 10-20 minutes and 1 weekly group meeting of 45-60 minutes on nutrition and on the emotional management of the disease. Supervised and incremental aerobic training, lasting at least 30 minutes, 5/6 days a week for a total of 12-14 sessions. The initial workload will be set between 50-70% of the maximum load (watts) determined starting from the 6MWT using the Hill equation and will be increased to reach a perception of moderate-intense fatigue and/or dyspnea. Supervised strength training of the lower limbs and upper limbs, lasting 30 minutes, 5/6 times a week for a total of 12-14 sessions. The workload will be calibrated to allow the execution of 12 consecutive repetitions and will be progressively increased by 0.5 kg in order to cause a moderate/intense fatigue and/or dyspnea. Group exercises aimed at improving flexibility of the trunk, lower and upper limbs, lasting at least 30 minutes, 5/6 days a week, for a total of 12-14 sessions.
Experimental: Intervention
Educational interventions, aerobic and strenght training, balance training.
Educational interventions, 3 individual sessions of 10-20 minutes and 1 weekly group meeting of 45-60 minutes on nutrition and on the emotional management of the disease. Supervised and incremental aerobic training, lasting at least 30 minutes, 5/6 days a week for a total of 12-14 sessions. The initial workload will be set between 50-70% of the maximum load determined from the 6MWT (Hill equation) and will be increased based on dyspnea. Supervised strength training of the lower limbs and upper limbs, lasting 30 minutes, 5/6 times a week for a total of 12-14 sessions. The workload will be progressively increased. Supervised balance training sessions lasting 30 minutes, 5/6 times a week for a total of 12-14 sessions. The sequence of the exercises will be personalized according to the result of the Berg Balance Scale and modified according to the progress.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Balance
Time Frame: 3 weeks
Berg Balance Scale (BBS). Scores range from 0 (worst) - 4 (best).
3 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Peripheral muscle strenght
Time Frame: 3 weeks
Five sit to stand test (5STS). Time < 14.9 seconds (best), >14.8 seconds (worst).
3 weeks
Gait speed
Time Frame: 3 weeks
4-meter gait speed test (4MGS). Time < 4.83 seconds (best), >4.82 seconds (worst).
3 weeks
Health status
Time Frame: 3 weeks
The COPD Assessment Test (CAT) score ranges from 0 (best) to 40 (worst).
3 weeks
Dyspnea
Time Frame: 3 weeks
Medical Research Council (mMRC) score ranges from 0 (best) to 4 (worst).
3 weeks
Dyspnea on daily life activities
Time Frame: 3 weeks
Barthel Dyspnea Index (BDI) total score ranges from 0 (best) to 100 (worst).
3 weeks
COPD Quality of life
Time Frame: 3 weeks
EuroQoL-5D total score ranges from 0 (worst) to 100 (best).
3 weeks
Exercise capacity
Time Frame: 3 weeks
Six-Minute Walking Test (6MWT) measures the maximum walked distance in meters (m) in a given time (6 minutes).
3 weeks
Confidence with balance
Time Frame: 3 weeks
Activities-specific Balance Confidence short form (ABC-6) Scale. Score from 0 (worst) to 100 (best).
3 weeks
Perceived change
Time Frame: 3 weeks
Global perceived effect (GPE) scale. Score range from 1 (best) to 7 (worst).
3 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2023

Primary Completion (Actual)

January 15, 2025

Study Completion (Actual)

January 19, 2026

Study Registration Dates

First Submitted

May 23, 2023

First Submitted That Met QC Criteria

July 25, 2023

First Posted (Actual)

August 2, 2023

Study Record Updates

Last Update Posted (Actual)

April 17, 2026

Last Update Submitted That Met QC Criteria

April 14, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COPD

Clinical Trials on Standard pulmonary rehabilitation program

Subscribe